-
Posted by
Two Blokes Apr 22 -
Filed in
Stock
-
15 views
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 22, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 therapies. While these treatments are revolutionizing obesity care by delivering significant weight loss, they also induce a concerning loss of muscle mass, which can compromise patients' mobility, strength, and quality of life.
